u/marit_laurent

Total transit includes a clearance stage that is not under the carrier’s control. Separating clearance time from carrier time is the first step in diagnosing any delay.

Push back: you cannot infer degradation from a temperature excursion alone. That is what testing is for.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

nothing containing this is approved anywhere yet

Are you comparing against phase 3 numbers for something else? They are not comparable.

Escalating faster than the schedule allows is the most frequently described regret on the site, and the mechanism is straightforward: tolerance is the

stubborn_batchlist_only is right that it was procedural. The procedure was not written down anywhere for you to follow.

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

Did you write anything down at the time?

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Which phase 2 arm are you quoting, and at what week?

Independent result added to the log — there are very few on that compound.

Adding the practical question — stocked or made to order, and what is the lead time.

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences. Those are decided by different bodies with different processes.

Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Has anyone posted an independent test on this compound recently?

Naming in this space is inconsistent. Several widely used names map to more than one molecule, so a catalogue number and a sequence beat a common name every time.

a telehealth intake that asks nothing has told you what it is

Cosigning on paperwork. The boring documents are the ones that matter when a process starts.

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

Is that intention-to-treat or completers?

money lost to a shop with nothing on file is the recurring story

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

a log is not a plan and it is not advice for anybody else

What does the local patient information leaflet say?

What is the one column you added late and wish you had from the start?

Are the missed weeks in there as blanks or dropped entirely?

Are you comparing against phase 3 numbers for something else? They are not comparable.

Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.

Most of what gets posted here is procedural rather than dramatic: a step skipped, a document not requested, a temperature not considered, a pace chosen out of impatience.

a lot of the confident posting here is extrapolation

Correction: that name covers two different molecules and the thread has been discussing both as one.

Naming in this space is inconsistent. Several widely used names map to more than one molecule, so a catalogue number and a sequence beat a common name every time.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

Are you being harder on yourself than you would be on somebody else posting this?

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

registry entry, protocol, publication — three different documents